Boehringer Ingelheim's worldwide Research & Development Sites
Research & development at Boehringer Ingelheim is conducted at four major research & development sites and three support centres worldwide. We employ more than 6,700 scientists, technicians and support staff, clinical monitors, statisticians and data managers. Clinical research is conducted in 58 countries all over the world.
The bridge between industry and academia is strengthened by the Research Institute of Molecular Pathology (IMP) in Vienna (Austria).
R&D Sites
- Biberach and Ingelheim, Germany
Research & Development Areas:
- Central Nervous System Diseases
- Metabolism Diseases
- Respiratory Diseases
- Non-clinical drug development
Country Website:
Boehringer Ingelheim website in Germany
- Ridgefield, USA
Research & Development Areas:
- Cardiovascular Diseases
- Immunology and inflammation
- Non-clinical drug development
Country Website:
Boehringer Ingelheim website in USA
- Vienna, Austria
Research Area:
Country Website:
Boehringer Ingelheim website in Austria
- Laval, Canada
Research Area:
Country Website:
Boehringer Ingelheim website in Canada
Support Centres
- Kobe, Japan
Support centre for molecular biology and non-clinical drug development:
- Support for international drug discovery activities
- Early drug formulation
- Specific pharmacokinetic investigations
Country Website:
Boehringer Ingelheim website in Japan
- Buenos Aires, Argentina
Support centre for non-clinical development:
- Support on drug formulation and manufacturing of medication for clinical trials
Country Website:
Boehringer Ingelheim website in Argentina
- Milan, Italy
Support centre for chemical synthesis:
- Support for synthesis in exploratory and lead optimisation projects
Country Website:
Boehringer Ingelheim website in Italy
